HanchorBio Expands Global Patent Protection for HCB101 with Taiwan Grant
Taiwan grant adds to issued patents in the United States and Japan, further strengthening HCB101’s cross-border IP estate and supporting long-term development and partnering strategy
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the Taiwan Intellectual Property Office has granted a patent covering HCB101, the company’s lead engineered SIRPα fusion protein, under the title “ENGINEERED SIRPα VARIANTS AND METHODS OF USE THEREOF.” The Taiwan patent certificate number is I916300.
The grant further enhances HanchorBio’s intellectual property position regarding the core molecular design and therapeutic application of HCB101 as the program progresses through clinical development and global partnership discussions.
HCB101 is a rationally engineered SIRPα fusion protein developed using HanchorBio’s proprietary FBDB™ platform. It is designed to target the CD47–SIRPα innate immune checkpoint with a differentiated profile intended to enhance blockade of CD47 on tumor cells while reducing binding to normal blood cells. This design is intended to support improved tolerability, broader combination potential, and greater clinical utility in immuno-oncology.
“The Taiwan patent grant further strengthens the global intellectual property foundation for HCB101 and reflects our ongoing commitment to developing a differentiated and strategically valuable program,” said Scott Liu, Ph.D., Chairman and Chief Executive Officer of HanchorBio. “With patents now issued in the United States, Japan, and Taiwan, we are broadening protection for the core innovation behind HCB101 in key jurisdictions for scientific leadership, clinical development, and future collaborations.”
The Taiwan patent is strategically significant not only because it provides protection in another Asian jurisdiction but also because it strengthens protection in HanchorBio’s local innovation hub, where the original invention and platform technologies were developed. For global investors and potential partners, securing protection in the home jurisdiction enhances the company’s control over the core intellectual property behind the program and deepens the patent portfolio supporting HCB101.
The Taiwan grant expands HanchorBio’s expanding global IP portfolio for HCB101. The program previously received U.S. Patent No. 12,447,195 in October 2025 and Japan Patent No. 7795041 in January 2026. Now that patents have been issued in the United States, Japan, and Taiwan, HanchorBio has established a strong early patent foundation across key jurisdictions related to the invention’s origin, pharmaceutical partnerships, and future commercial strategy.
As HCB101 advances through clinical development, HanchorBio believes this growing patent portfolio will play a key role in protecting the program’s unique molecular design, enhancing its competitive position, and supporting future licensing and strategic collaborations. The U.S., Japan, and Taiwan grants collectively provide issued patent protection across a significant cross-border IP footprint, boosting the asset’s long-term strategic value as development continues.
HanchorBio is advancing a pipeline of innovative biologics for oncology and autoimmune diseases through its proprietary platform technologies. The company remains focused on combining scientific innovation, clinical development, and global intellectual property strategies to advance new therapies for patients with significant unmet medical needs.
About HCB101
HCB101 is an engineered SIRPα–IgG4 Fc fusion protein designed to target the CD47–SIRPα innate immune checkpoint with a differentiated profile intended to enhance tumor-cell blockade while reducing binding to normal blood cells. Developed using HanchorBio’s proprietary FBDB™ platform, HCB101 is being advanced as a potential backbone for innate immune checkpoint therapy in oncology.
About HanchorBio
HanchorBio (TPEx: 7827) is a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and autoimmune diseases. With operations in Taipei, Shanghai, and the San Francisco Bay Area, the company is advancing a pipeline of differentiated biologics built on its proprietary Fc-based designer biologics (FBDB™) platform. HanchorBio’s programs are designed to address unmet medical needs through advanced molecular engineering, clinical development, and scalable manufacturing strategies.